Showing 3601-3610 of 7135 results for "".
- Dersimelagon Improves Sunlight Tolerance in EPP and XLPhttps://practicaldermatology.com/news/dersimelagon-improves-sunlight-tolerance-in-epp-and-xlp/2486452/Dersimelagon, an oral melanocortin 1 receptor (MC1R) agonist, significantly improved sunlight tolerance in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), according to Phase 3 INSPIRE trial results presented by Amy Dickey Yeung, MD, at the American Academy of
- Real-World Data Confirm Upadacitinib Effectiveness Across Body Regionshttps://practicaldermatology.com/news/real-world-data-confirm-upadacitinib-effectiveness-across-body-regions/2486450/Real-world evidence from the AD-VISE study demonstrates consistent and robust effectiveness of upadacitinib across body regions in patients with atopic dermatitis (AD), reinforcing outcomes observed in controlled clinical trials, according to data discussed by Melinda Gooderham, MD, MSc, at the A
- Roflumilast Cream Shows Safety and Efficacy in Infants With Atopic Dermatitishttps://practicaldermatology.com/news/roflumilast-cream-shows-safety-and-efficacy-in-infants-with-atopic-dermatitis/2486449/Roflumilast cream 0.05%, a topical phosphodiesterase 4 (PDE4) inhibitor, demonstrated favorable safety and clinically meaningful efficacy in infants with atopic dermatitis (AD), according to results from the Phase 2 INTEGUMENT-INFANT study presented by Lawrence F. Eichenfield, MD, at the American
- Envudeucitinib Outperforms Placebo and Apremilast in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/envudeucitinib-outperforms-placebo-and-apremilast-in-phase-3-psoriasis-trials/2486447/Envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated significant efficacy and a favorable safety profile in patients with moderate-to-severe plaque psoriasis, according to Phase 3 data from the ONWARD 1 and ONWARD 2 trials presented by Andrew Blauvelt, MD, MBA,
- Abrocitinib Shows Efficacy in Chronic Hand Eczema in Phase II Trialhttps://practicaldermatology.com/news/abrocitinib-shows-efficacy-in-chronic-hand-eczema-in-phase-ii-trial/2486424/Abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis, demonstrated significant efficacy in patients with chronic hand eczema (CHE) of diverse etiologies in a Phase II randomized trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- Oral STAT6 Degrader KT-621 Shows Early Promise in Atopic Dermatitishttps://practicaldermatology.com/news/oral-stat6-degrader-kt-621-shows-early-promise-in-atopic-dermatitis/2486423/A first-in-class oral STAT6 degrader, KT-621, demonstrated early clinical activity, robust biomarker suppression, and a favorable safety profile in adults with moderate-to-severe atopic dermatitis (AD), according to Phase 1b data presented by Mahta Mortezavi, MD, at the American Academy of Dermat
- MG-K10 Shows Sustained Efficacy in Atopic Dermatitis Through 52 Weekshttps://practicaldermatology.com/news/mg-k10-shows-sustained-efficacy-in-atopic-dermatitis-through-52-weeks/2486421/A long-acting anti–IL-4 receptor alpha monoclonal antibody, MG-K10, demonstrated sustained efficacy and a favorable safety profile through 52 wee
- Povorcitinib Shows Durable Efficacy in HS in Phase 3 STOP-HS Trialshttps://practicaldermatology.com/news/povorcitinib-shows-durable-efficacy-in-hs-in-phase-3-stop-hs-trials/2486420/Late-breaking results from the Phase 3 STOP-HS1 and STOP-HS2 trials presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting showed that povorcitinib, an oral JAK1-selective inhibitor, achieved sustained efficacy and a manageable safety profile through 54 weeks in patients with
- Prurigo Nodularis Diagnosis Centers on Clinical Recognition, Not Biopsy, Dr. Elmariah Sayshttps://practicaldermatology.com/news/prurigo-nodularis-diagnosis-centers-on-clinical-recognition-not-biopsy-dr-elmariah-says/2486417/A pragmatic, clinically driven approach is necessary for diagnosing prurigo nodularis (PN), and a biopsy is often unnecessary when key features are present, according to a talk by Sarina Elmariah, MD, FAAD, at the 2026 American Academy of Dermatology (AAD) Annual Meeting. “It is these thre
- Prurigo Nodularis Linked to Elevated Cardiovascular Risk, Expanding View of Systemic Diseasehttps://practicaldermatology.com/news/prurigo-nodularis-linked-to-elevated-cardiovascular-risk-expanding-view-of-systemic-disease/2486416/Growing evidence indicates prurigo nodularis (PN) is associated with increased cardiovascular risk, reinforcing the disease’s systemic nature and the potential consequences of untreated inflammation, according to a talk by Shawn Kwatra, MD, at the 2026 American Academy of Dermatology Annual Meeti